openPR Logo
Press release

Hereditary Angioedema Therapeutics Market - Forecast to 2026

Hereditary Angioedema Therapeutics Market

Hereditary Angioedema Therapeutics Market

As per the research conducted by GME, the Global Hereditary Angioedema Therapeutics Market will grow with a CAGR value of 8.2%. Population growth, as well as lifestyle changes, improved insurance programs, and increased efforts by pharmaceutical and biotechnology companies to develop new products and solutions for the industry, are expected to fuel market revenue for Hereditary Angioedema in the years ahead.

Browse 153 Market Data Tables and 113 Figures spread through 183 Pages and in-depth TOC on “Global Hereditary Angioedema Therapeutics Market - Forecast to 2026" https://www.globalmarketestimates.com/market-report/global-hereditary-angioedema-therapeutics-market-3095

By Drug Class [C1-esterase Inhibitor, Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Others], By Treatment Type [Prophylaxis, On-demand], By Route of Administration [Intravenous, Subcutaneous, Oral], By Region (North America, Asia Pacific, CSA, Europe, and the Middle East and Africa); End-User, Landscape, Company Market Share Analysis, and Competitor Analysis
Key Market Insights
• Hereditary angioedema is a relatively uncommon genetic disorder. Rare diseases have become more common in recent years as global monitoring of their occurrence has increased over the last few decades.
• The Hereditary Angioedema Association is predicted to play an important role in spreading new therapies around the world.
• The swelling of tissues in the limbs, feet, digestive tract, face, or airway is caused by the flow of blood or lymphatic fluid, or the constant retention of fluids outside the blood vessels.
• According to the National Institutes of Health, hereditary angioedema affects about one in every 50,000 people.
• Subcutaneous injections as a mode of drug administration are expected to see a rise in demand due to an increase in demand for easy-to-use patients.
• BioCryst Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; Pharming Group N.V.; CSL Limited; Shire Plc; Attune Pharmaceuticals, Inc.; Adverum Biotechnologies, Inc.; and KalVista Pharmaceuticals, Inc. are the top players in the Hereditary Angioedema Therapeutics Market.
• In April 2021, BioCryst’s product ORLADEYOTM (berotralstat), the first oral, once-daily therapy to prevent attacks in patients with hereditary angioedema, has been approved by the European Commission.

Browse the Report @ https://www.globalmarketestimates.com/market-report/global-hereditary-angioedema-therapeutics-market-3095

Drug Class Outlook (Revenue, USD Billion, 2021-2026)
• C1-esterase inhibitor
• Bradykinin B2 receptor antagonist
• Kallikrein inhibitor
• Others

Treatment Type Outlook (Revenue, USD Billion, 2021-2026)
• Prophylaxis
• On-demand

Route of Administration Outlook (Revenue, USD Billion, 2021-2026)
• Intravenous
• Subcutaneous
• Oral

Regional Outlook (Revenue, USD Billion, 2021-2026)
North America
• The U.S.
• Canada
• Mexico
Europe
• Germany
• UK
• France
• Spain
• Italy
• Rest of Europe
Asia Pacific
• China
• India
• Japan
• South Korea
• Australia
• Rest of APAC
Central & South America
• Brazil
• Argentina
• Rest of CSA
Middle East & Africa
• Saudi Arabia
• UAE
• Rest of MEA

Contact: Yash Jain
Email address: yash.jain@globalmarketestimates.com
Phone Number: +16026667238
Website: https://www.globalmarketestimates.com/
Check our Latest Blogs: https://www.globalmarketestimates.com/blog-posts.php

B-502, Kemp Plaza, Mindspace, Malad West, Mumbai: 400 064, India

Global Market Estimates is an India based market research and consulting company. The company provides syndicated research reports, customised research reports and consulting services to their clients and helps them achieve their business goals on a commercial level. Global Market Estimates database is used by the world's well known and prolific academic institutions and Fortune 500 companies to understand the global and regional business environment to excel in their business goals.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Hereditary Angioedema Therapeutics Market - Forecast to 2026 here

News-ID: 2282832 • Views:

More Releases from Global Market Estimates Research & Consultants

Global Flare Monitoring Market Size & Trends
Global Flare Monitoring Market Size & Trends
According to a new market research report published by Global Market Estimates, the global flare monitoring market is expected to grow at a CAGR of 6.5% from 2024 to 2029. Global flare monitoring market growth is driven by factors such as safety and risk management and growing emphasis on reduction of emissions. Unlock the Executive Summary of the report at only USD 249. Book a call now: https://tidycal.com/yashsushiljain/unlock-strategic-insights-press-release Key Market Insights • As per
Global Fiber Optic Component System Market Size & Trends
Global Fiber Optic Component System Market Size & Trends
According to a new market research report published by Global Market Estimates, the global fiber optic component system market is expected to grow at a CAGR of 8.46 % from 2024 to 2029. Global fiber optic component system market growth is driven by factors such as growing demand for safety regulations and technological developments. Unlock the Executive Summary of the report at only USD 249. Book a call now: https://tidycal.com/yashsushiljain/unlock-strategic-insights-press-release Key Market
Global Rechargeable Battery Market Size & Trends
Global Rechargeable Battery Market Size & Trends
According to a new market research report published by Global Market Estimates, the global rechargeable battery market is expected to grow at a CAGR of 15.4% from 2024 to 2029. Rechargeable batteries have been growing in popularity due to their inherent superiority over disposable batteries in environmental pollution. As rechargeable batteries can be recharged after every use, they cause much lower environmental degradation as compared to disposable batteries, which are discarded
Global Asset Management Solution Market Size & Trends
Global Asset Management Solution Market Size & Trends
According to a new market research report published by Global Market Estimates, the global asset management solution market is projected to grow at a CAGR of 35.1% from 2024 to 2029. The growth of the global asset management solution market is driven by increasing demand for efficient and automated asset tracking and management, the growing need for compliance and risk management in various industries (IoT), and the expanding adoption of cloud-based

All 5 Releases


More Releases for Hereditary

Hereditary Testing Market Size – Forecasts to 2026
The results analyzed by GME showed that the Global Hereditary Testing Market will grow with a CAGR value of 7.1 percent, to hit xx billion USD by 2026. During the forecast timeframe, growth is expected to be driven by growing expenditure on R&D activities and the rising incidence of chronic diseases worldwide. The development may be attributed to the advancement of genetic testing services and the growing demand for personalized
Potential Opportunities of Hereditary Angioedema Treatment Market
The global hereditary angioedema treatment market to gain from increasing incidences of genetic mutation. Recently Fortune Business Insights, published a report titled, "Hereditary Angioedema Treatment Market Size, Share and Global Trend by Drug Class (C-1 Esterase Inhibitors, Bradykynin Receptor Antagonist, Kallikrein Inhibitors), Application (Prophylaxis, Treatment), Route of Administration (IV, Subcutaneous), Distribution Channel (Hospital Pharmacy, Retail Pharmacy) and Geography Forecast till 2025." As per the report, the global hereditary angioedema treatment
Hereditary Angioedema Market Global Comprehensive Research 2020
Global Hereditary Angioedema Market research report published by market insight reports explores the current outlook in global and key regions from the perspective of Major Players, Countries, Product types and end industries. This report analyzes top players in the global market, and divides the Market into several parameters. This Hereditary Angioedema Market research report identifies the competitive landscape of industries to understand the competition at International level. This report study describes
Hereditary Angioedema Market Current Overview by 2025
flow of blood or lymphatic fluid, continuous accumulation of fluids outside of the blood vessels, results in swelling of tissues in the arms, feet, intestinal tract, face, or airway. Stress or Minor trauma may also trigger an attack, Swelling in the airway can limit breathing and prompt to life-debilitating obstruction of the airway. Around 33% of individuals with this condition faces non-itchy rash called erythema marginatum at the time of
Hereditary Angioedema Market is propelled by rise in hereditary angioedema (HAE) …
Some of the prominent names operating in the global hereditary angioedema market are Pharming Group NV, Shire plc, CSL Limited, Ionis Pharmaceuticals, Inc., iBio Inc., and BioCryst Pharmaceuticals, Inc. As per a report by Transparency Market Research, the global hereditary angioedema market will likely rise at a healthy 9.1% CAGR between 2017 and 2025 to become worth US$3.81 bn by 2025 from US$ 1.73 bn in 2016. Read Report Overview: https://www.transparencymarketresearch.com/hereditary-angioedema-market.html Superior Healthcare
Hereditary Angioedema Market : Global Forecast over 2025
As per a report by Transparency Market Research, the global hereditary angioedema market will likely rise at a healthy 9.1% CAGR between 2017 and 2025 to become worth US$3.81 bn by 2025 from US$ 1.73 bn in 2016. Superior Healthcare Facilities Makes North America Market Leader Depending upon the class of drugs, the global hereditary angioedema market can be segmented into C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, and Kallikrein Inhibitor,